1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

6 Months Ended

Jun. 30, 2018

Summary Of Significant Accounting Policies Tables

Disaggregation of revenue

Revenue streams from sales of CellerateRX and HemaQuell products for the six-months ended June 30, 2018 and 2017 are presented below.	Six-months Ended
	June, 30
	2018		2017
CellerateRX Powder	$	3,876,693	$	2,748,573
CellerateRX Gel		265,462		213,459
HemaQuell		25,183		-
Other revenue		56,539		96,114
Total Revenue	$	4,223,877	$	3,058,146